Skip to main content

Animations

MJFF Publications

7711 - 7720 of 8823 Results
Title
Year
  • Year
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2021
  • 2021
  • 2021
  • Summary Details
    OPEN
    Title: Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways
    Journal Name: Neuron
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuron.2020.02.034
    Citation Count: 252
  • Summary Details
    RESTRICTED
    Title: Effects of subthalamic nucleus deep brain stimulation on neuronal spiking activity in the substantia nigra pars compacta in a rat model of Parkinson’s disease
    Journal Name: Neuroscience Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neulet.2020.135443
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.05.047
    Citation Count: 22
  • Summary Details
    OPEN
    Title: Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.04.002
    Citation Count: 54
  • Summary Details
    OPEN
    Title: The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.027
    Citation Count: 42
  • Summary Details
    RESTRICTED
    Title: Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.026
    Citation Count: 40
  • Summary Details
    RESTRICTED
    Title: GBA variation and susceptibility to multiple system atrophy
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.007
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/alz.12480
    Citation Count: 42
  • Summary Details
    OPEN
    Title: Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/alz.12353
    Citation Count: 117
  • Summary Details
    RESTRICTED
    Title: Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.01.024
    Citation Count: 2
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.